 Connection
Robert McQueen to United States
This is a "connection" page, showing publications Robert McQueen has written about United States.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.739 |
|
|
|
-
Padula WV, McQueen RB. Should Early-Stage NIH Funding Influence Pharmaceutical Drug Pricing? Value Health. 2026 02; 29(2):242-246.
Score: 0.066
-
Zemplenyi AT, Chen NC, Anderson KE, Adamson B, DiStefano MJ, Nair KV, McQueen RB. Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab. Pharmacoeconomics. 2025 09; 43(9):1147-1160.
Score: 0.065
-
Zemplenyi A, Leonard J, Wright GC, DiStefano MJ, Nair K, Anderson KE, McQueen RB. Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI's Gene Therapy Access Model. Pharmacoeconomics. 2025 05; 43(5):583-594.
Score: 0.064
-
Anderson KE, Chaiyakunapruk N, Gutierrez EJ, Schmutz HW, Rose MR, Brixner D, McQueen RB. State Out-Of-Pocket Caps On Insulin Costs: No Significant Increase In Claims Or Utilization. Health Aff (Millwood). 2024 08; 43(8):1137-1146.
Score: 0.061
-
DiStefano MJ, Zemplenyi A, Anderson KE, Mendola ND, Nair KV, McQueen RB. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb; 24(2):171-180.
Score: 0.059
-
DiStefano MJ, Zemplenyi A, McQueen RB. Assessing clinical benefit in the Medicare Drug Price Negotiation Program: A 2-step approach for improving transparency, consistency, and meaningful patient engagement. J Manag Care Spec Pharm. 2024 Mar 01; 30(3):252-258.
Score: 0.059
-
Zemplenyi A, Leonard J, DiStefano MJ, Anderson KE, Wright GC, Mendola ND, Nair K, McQueen RB. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid. Pharmacoeconomics. 2024 03; 42(3):319-328.
Score: 0.058
-
McQueen RB, Inotai A, Zemplenyi A, Mendola N, Németh B, Kalo Z. Multistakeholder Perceptions of Additional Value Elements for United States Value Assessment of Health Interventions. Value Health. 2024 01; 27(1):15-25.
Score: 0.058
-
Mendola ND, Oehrlein E, Perfetto EM, Westrich K, McQueen RB. Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States. J Manag Care Spec Pharm. 2022 Oct; 28(10):1190-1196.
Score: 0.054
-
Padula WV, McQueen RB. Expanding the Role of the Patient-Centered Outcomes Research Institute: Reauthorization and Facilitating Value Assessments. Appl Health Econ Health Policy. 2019 12; 17(6):757-759.
Score: 0.044
-
McQueen RB, Whittington MD, Chapman RH, Kumar VM, Campbell JD. Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". Pharmacoeconomics. 2019 07; 37(7):963-964.
Score: 0.043
-
DiStefano MJ, McQueen RB, Zheng H, Gyamfi HG, Ameyaw D, Campbell JD, Zemplenyi A. Opportunities for CMS to Further Specify and Broaden Its Approach to Assessing Unmet Medical Need in the Context of the Medicare Drug Price Negotiation Program. Appl Health Econ Health Policy. 2026 03; 24(2):261-269.
Score: 0.017
-
DiStefano MJ, McQueen RB, Gao V, Klein MP, Snell-Bergeon JK, Polsky S. The Cost of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Type 1 Diabetes Pregnancies in the United States: A Cost-Consequences Analysis Using Real-World Evidence. Diabetes Technol Ther. 2025 04; 27(4):329-333.
Score: 0.016
-
Hoffmann S, White AE, McQueen RB, Ahn JW, Gunn-Sandell LB, Scallan Walter EJ. Economic Burden of Foodborne Illnesses Acquired in the United States. Foodborne Pathog Dis. 2025 01; 22(1):4-14.
Score: 0.015
-
Ahn JW, Scallan Walter E, White AE, McQueen RB, Hoffmann S. Identifying Sepsis From Foodborne Hospitalization: Incidence and Hospitalization Cost by Pathogen. Clin Infect Dis. 2022 09 14; 75(5):857-866.
Score: 0.013
-
Dhaliwal S, Hoffmann S, White A, Ahn JW, McQueen RB, Scallan Walter E. Cost of Hospitalizations for Leading Foodborne Pathogens in the United States: Identification by International Classification of Disease Coding and Variation by Pathogen. Foodborne Pathog Dis. 2021 11; 18(11):812-821.
Score: 0.013
-
Carlson JJ, Walton SM, Basu A, Chapman RH, Campbell JD, McQueen RB, Pearson SD, Touchette DR, Veenstra D, Whittington MD, Ollendorf DA. Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States. Pharmacoeconomics. 2019 11; 37(11):1321-1327.
Score: 0.011
-
Whittington MD, McQueen RB, Ollendorf DA, Chapman RH, Kumar VM, Synnott PG, Agboola F, Campbell JD. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. J Manag Care Spec Pharm. 2019 Jan; 25(1):80-87.
Score: 0.010
-
Libby AM, Ghushchyan V, McQueen RB, Slejko JF, Bainbridge JL, Campbell JD. Economic differences in direct and indirect costs between people with epilepsy and without epilepsy. Med Care. 2012 Nov; 50(11):928-33.
Score: 0.007
-
Libby AM, Ghushchyan V, McQueen RB, Campbell JD. Economic grand rounds: psychological distress and depression associated with job loss and gain: the social costs of job instability. Psychiatr Serv. 2010 Dec; 61(12):1178-80.
Score: 0.006
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|